The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Mersana Therapeutics Q3 EPS $(0.63) Misses $(0.58) Estimate
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.58) by 8.62 percent. This is a 90.91 percent decrease over losses of $(0.33) per share
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings
Mersana Therapeutics Inc (NASDAQ:MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference. XMT-2056…
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
Mersana Therapeutics Announces Target And Presents New Preclinical Data For XMT-2056, First Immunosynthen STING-Agonist ADC, At AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical
Mersana Therapeutics To Announce Target And Present New Preclinical Data For XMT-2056 At The AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical
45 Stocks Moving In Monday’s Mid-Day Session
Gainers
Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets.
